NCLA Nuclea Energy Inc.

BEARISH Impact: 6/10 F-1/A
Horizon weeks Filed Jun 9, 2026 Processed 3d 16h ago SEC 0001213900-26-066889
Foreign IPO amendment

Executive Summary

Nuclea Energy Inc. filed Amendment No. 3 to its F-1 registration statement for an initial public offering of 5,555,556 common shares at an estimated price range of $8.00-$10.00 per share (midpoint $9.00), with a concurrent resale of 2,817,294 shares by selling shareholders. The company is a pre-revenue, development-stage nuclear microreactor developer with no revenue since inception, cumulative net losses of $2.2M as of Dec 31, 2025, and a going concern qualification. Net proceeds of ~$45.5M will fund an 18-month development roadmap for its Morpheus Microreactor, but the company faces significant technical, regulatory, and capital risks.

Key Financial Metrics

Price Range
$8.00-$10.00 per share

Actionable Insight

Monitor IPO pricing and completion; track use of proceeds against stated milestones (R&D lab, regulatory filings, third-party validation). Expect high volatility post-IPO given pre-revenue status and binary regulatory outcomes. Subsequent capital raises likely dilutive.

Key Facts

  • IPO of 5,555,556 common shares at $8.00-$10.00 per share; resale of 2,817,294 shares by selling shareholders.
  • Pre-revenue, development-stage company since incorporation in August 2023.
  • Net loss of $1,945,868 for six months ended Dec 31, 2025; accumulated deficit of $2,198,532.
  • Cash of $3,230,952 as of Dec 31, 2025; net IPO proceeds estimated at ~$45.5 million.
  • 18-month development roadmap funded by IPO proceeds; commercialization target 2030-2031.
  • High risks: unproven technology, regulatory approval, HALEU fuel supply, need for significant additional capital.
  • Plans to list on NYSE under ticker NCLA.
  • Contingent Moltex Asset Acquisition for ~$8.5M (distressed assets from UK insolvency).

Financial Impact

Net IPO proceeds of ~$45.5M to fund 18-month roadmap; ongoing losses require substantial future capital (potentially hundreds of millions).

cashshare countaccumulated deficit

Risk Factors

  • No revenue or path near-term to revenue; continued operating losses.
  • Morpheus Microreactor is first-of-a-kind; technical feasibility unvalidated.
  • Regulatory approval from CNSC and NRC uncertain; timelines 2028-2030.
  • HALEU fuel supply chain not commercially available.
  • Substantial additional capital needed (potentially hundreds of millions).
  • Moltex Asset Acquisition may not close; distressed assets risk.
  • Insider concentration: 25.4% each for two founders post-IPO.

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
F-1/A Filing (Primary)0001213900-26-066889
Document: ea027004316ex10-10.htm0001213900-26-066889
Document: ea027004316ex23-1.htm0001213900-26-066889
Document: 0001213900-26-066889-index-headers.html0001213900-26-066889
Document: 0001213900-26-066889-index.html0001213900-26-066889
Document: 0001213900-26-066889.txt0001213900-26-066889

US Market Status

Market Closed — Opens Mon (47h 32m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access